Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Sep 18, 2013
PTC THERAPEUTICS TO PRESENT AT EUROPEAN PEDIATRIC NEUROLOGY SOCIETY CONGRESS SOUTH PLAINFIELD, NJ – September 18, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that two abstracts have been accepted for the 10th European Pediatric Neurology Society Congress (EPNS) in Brussels,
Additional Formats
Aug 29, 2013
PTC THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES SOUTH PLAINFIELD, NJ – August 29, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in following conferences in September: - Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC
Additional Formats
Aug 26, 2013
-Two publications further validate the use of 6MWT as a primary endpoint in Duchenne Muscular Dystrophy (DMD) clinical trials-
Additional Formats
Aug 12, 2013
-- Conference call to be held today at 4:30 p.m. ET --
Additional Formats
Supporting Materials
Aug 08, 2013
- PTC to Receive $10 Million Payment from Roche -
Additional Formats
Aug 06, 2013
PTC THERAPEUTICS TO PRESENT AT WEDBUSH CONFERENCE SOUTH PLAINFIELD, NJ – August 6, 2013 –PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs, Chief Financial Officer of PTC Therapeutics will present a company overview at the Wedbush Securities Life Sciences Management
Additional Formats
Aug 05, 2013
PTC THERAPEUTICS TO HOST SECOND QUARTER 2013 FINANICAL RESULTS CONFERENCE CALL AND WEBCAST SOUTH PLAINFIELD, NJ – August 5, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will report financial results for the second quarter ended June 30, 2013 following the
Additional Formats
Jun 25, 2013
PTC Therapeutics Closes Initial Public Offering SOUTH PLAINFIELD, NJ – June 25, 2013 – PTC Therapeutics, Inc. (PTC) (NASDAQ: PTCT) today announced the closing of its initial public offering of 9,627,800 shares of common stock at a public offering price of $15.00 per share, before
Additional Formats
Jun 20, 2013
PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING SOUTH PLAINFIELD, NJ – June 20, 2013 – PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts.
Additional Formats
Jun 03, 2013
PTC THERAPEUTICS APPOINTS SHANE KOVACS AS CHIEF FINANCIAL OFFICER SOUTH PLAINFIELD, NJ – June 3, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Shane Kovacs as Chief Financial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr.
Additional Formats